The robustness of Quantitative Phase Imaging (QPI) has enabled QPI to be used in applications to answer both research and clinical questions. QPI requires no labels, is non-destructive, and has nanoscale sensitivity to 3-d morphology. Various applications have included recording cellular force dynamics, identifying parasite-infected red blood cells, detecting cancer prognosis from colon cancer samples, and most recently predicting therapeutic sensitivity from live cell biomass accumulation measurements in patient derived xenograft (PDX) mice. However, challenges remain for clinical adoption, as QPI-based methods must first be proven more effective than current standards of care and patient inconvenience and costs must be minimized. Here we applied basic upgrades to previously described High Speed Live Cell Interferometry (HSLCI) to predict <i>in vivo</i> and <i>in vitro</i> PDX mouse tumor sensitivity to a range of cancer drugs from only Fine Needle Biopsy of the tumor. As demonstrated by our group and many others, the applications of QPI are not limited to the clinical realm. Using HSLCI, we revealed the growth dynamics of senescent and control H460 lung large cell carcinoma cells treated with cancer chemotherapy. The continued improvements in optics and throughput of QPI promise to answer many more clinical and basic science questions.